Import from '@/components/mdx'

Can I Take St. John's Wort with Lantus (Insulin Glargine)?

The short answer: no, this combination is not safe to self-manage

St. John's Wort and Lantus should not be combined without direct clinician oversight. The herb acts on multiple pathways that influence blood glucose regulation, and those effects sit on top of an already tight dosing relationship between basal insulin and your glucose levels. You are not looking at one clean drug-drug interaction here. You are looking at several overlapping mechanisms that pull blood sugar in opposite directions depending on the dose, your metabolic state, and where you are in your menstrual cycle or menopausal transition.

This matters more for women than standard interaction databases sometimes communicate. Blood glucose regulation is not hormonally neutral. Estrogen, progesterone, and cortisol all alter insulin sensitivity across your cycle, across perimenopause, and across the postpartum period. Adding a pharmacologically active herb into that mix creates a moving target that is difficult to manage even in a clinical setting.

What is St. John's Wort and why do women use it?

St. John's Wort (Hypericum perforatum) is an over-the-counter herbal supplement used most often for mild to moderate depression. Studies estimate that roughly 17 percent of U.S. Adults using prescription medications also take herbal supplements, and St. John's Wort sits consistently in the top-ten list of supplements used by women.

Women are its primary consumers. The most common reasons include:

• Mild to moderate low mood or depression
• Perimenopausal mood changes and irritability
• Premenstrual dysphoric disorder (PMDD)
• Anxiety (though evidence here is limited)

The perimenopausal angle matters. Perimenopause is a time when both mood symptoms and metabolic shifts collide. Many women develop insulin resistance or progress to type 2 diabetes during this transition, and some of those same women reach for St. John's Wort for mood support without realizing they are combining it with a basal insulin that requires precise dosing.

Active compounds in St. John's Wort

The two most pharmacologically studied compounds are hypericin and hyperforin. Hyperforin is responsible for the majority of the clinically significant drug interactions, particularly its induction of CYP3A4, CYP2C9, and P-glycoprotein. A 2004 review in the British Journal of Clinical Pharmacology confirmed that standardized extracts containing high hyperforin content produce the most pronounced enzyme induction.

Products labeled "low-hyperforin" do not eliminate this risk. They may reduce it, but clinical data on low-hyperforin formulations and drug interactions in women with diabetes are thin. Treat all commercially available St. John's Wort as a CYP inducer until proven otherwise.

How does St. John's Wort interact with Lantus?

Insulin glargine is not metabolized by CYP enzymes. It is broken down by proteolytic degradation at the subcutaneous injection site and in the liver. That means the CYP3A4 induction that makes St. John's Wort such a problem for drugs like warfarin, cyclosporine, and oral contraceptives is not the primary concern with Lantus.

The interaction is predominantly pharmacodynamic. Both agents affect blood glucose, and they can push it in conflicting directions.

Mechanism 1: St. John's Wort has direct hypoglycemic properties

This is the part most women do not hear about in mainstream sources. Several in vitro and animal studies, and a small number of human observations, suggest that constituents of Hypericum perforatum may lower blood glucose through mechanisms that include increased glucose uptake and inhibition of hepatic glucose output. A 2010 study published in Phytomedicine found that hyperforin stimulated glucose uptake in 3T3-L1 adipocytes through a mechanism partly resembling insulin signaling. If this effect translates to clinical practice in women already using a basal insulin, the combination could push glucose too low, particularly overnight when Lantus is at its most active relative to fasting glucose.

Mechanism 2: St. John's Wort may also worsen glycemic control

Here is the contradiction that makes this interaction genuinely unpredictable: other evidence suggests St. John's Wort impairs glucose tolerance in some people. A 2004 clinical study in Clinical Pharmacology and Therapeutics found altered pharmacokinetics of co-administered agents in subjects taking St. John's Wort, with downstream effects on metabolic markers. The CYP2C9 induction pathway is relevant here because several oral antidiabetic drugs (not Lantus itself, but drugs often co-prescribed with it) are CYP2C9 substrates. If you are on Lantus plus metformin plus a sulfonylurea, adding St. John's Wort creates a cascade of interactions that is very difficult to predict.

Mechanism 3: Indirect effects via oral contraceptive failure

This matters specifically for reproductive-age women with type 1 or type 2 diabetes. St. John's Wort is a well-documented inducer of CYP3A4 and P-glycoprotein, and it reduces plasma concentrations of ethinyl estradiol and progestins in combined oral contraceptives. The FDA has warned that St. John's Wort reduces the effectiveness of oral contraceptives, which can lead to unintended pregnancy. An unplanned pregnancy in a woman on insulin glargine carries significant management complexity, because insulin requirements shift dramatically by trimester. This is not a theoretical concern. It is a recognized failure mechanism.

Mechanism 4: Serotonin-mediated effects on insulin secretion

Serotonin receptors are expressed in pancreatic beta cells, and serotonin itself plays a role in insulin secretion. St. John's Wort is a serotonin reuptake inhibitor. Research published in Nature Medicine demonstrated that serotonin signaling in beta cells modulates insulin release during pregnancy. Whether this translates to a clinically meaningful change in endogenous insulin secretion in non-pregnant women using the supplement is not yet established. Data are extrapolated from basic science, not from randomized trials in women with type 1 or type 2 diabetes.

The way to think about this interaction is not as a single mechanism but as a four-layer risk stack: (1) direct hypoglycemic properties of the herb competing with or amplifying Lantus, (2) potential worsening of glycemic control through CYP-mediated changes to co-prescribed oral antidiabetics, (3) contraceptive failure risk in reproductive-age women on insulin, and (4) serotonin-mediated shifts in endogenous insulin secretion that add noise to an already complex picture. No single published trial in women quantifies the net clinical effect. That evidence gap is itself a reason for caution.

How this plays out differently across your life stage

Reproductive years (ages 18 to 40)

If you are managing type 1 or type 2 diabetes with Lantus and you are of reproductive age, the contraceptive failure risk from St. John's Wort is your most immediate concern. Combined oral contraceptives are a common choice in this group, and the induction of CYP3A4 by St. John's Wort can cut circulating ethinyl estradiol levels by approximately 40 percent. The ACOG Practice Bulletin on combined hormonal contraceptives lists St. John's Wort as a drug that significantly decreases contraceptive effectiveness and advises against concurrent use or recommends a backup method.

On top of that, insulin sensitivity shifts across the menstrual cycle. Luteal phase estrogen and progesterone peaks are associated with relative insulin resistance, meaning your Lantus dose requirement changes predictably across the month. Adding an herb with variable glucose effects makes cycle-based glucose management much harder.

Perimenopause (typically ages 44 to 54)

This is the group most likely to combine St. John's Wort with Lantus, because mood symptoms and metabolic disease overlap heavily here. Estrogen decline during perimenopause increases visceral fat and worsens insulin resistance. Many women are diagnosed with type 2 diabetes for the first time during this window and are initiated on insulin sooner than they expected.

At the same time, perimenopausal mood fluctuations drive supplement use. St. John's Wort shows modest benefit for mild to moderate depression, but the evidence for perimenopause-specific mood symptoms is not strong enough to justify the interaction risk with insulin. A Cochrane review of interventions for perimenopausal depression did not find sufficient evidence to recommend St. John's Wort specifically for this population.

Post-menopause

Post-menopausal women on insulin face a different glycemic pattern. Without cyclical hormone fluctuations, glucose levels may be somewhat more stable, but the absence of estrogen also removes a degree of cardiovascular and metabolic protection. If you are post-menopausal, on Lantus, and considering St. John's Wort for mood, the conversation should start with your clinician about evidence-based options for depression that carry no interaction risk with your insulin regimen.

Pregnancy and lactation safety

Pregnancy: do not use St. John's Wort.

St. John's Wort does not have a formal FDA pregnancy category under the old letter system, but the available human and animal data do not support its use in pregnancy. A 2009 systematic review in the Canadian Journal of Clinical Pharmacology found insufficient safety data to recommend St. John's Wort during pregnancy and noted evidence of uterine stimulant activity in animal models. The herb should be stopped before attempting to conceive, and you should discuss timeline with your clinician because enzyme induction from St. John's Wort takes approximately two weeks to resolve after stopping.

Insulin glargine in pregnancy is a different matter entirely. Lantus is used in pregnancy under close monitoring, though ACOG's guidance on pregestational diabetes emphasizes that human insulin analogs, including insulin glargine, should be used with individualized dosing because insulin requirements increase substantially in the second and third trimesters. Lantus itself does not cross the placenta in clinically significant amounts based on available data, though studies are limited.

Lactation:

St. John's Wort is transferred into breast milk. A 2007 study in Breastfeeding Medicine detected hyperforin in the breast milk of nursing mothers taking standardized St. John's Wort extract, and infant exposure through milk is not zero. Colic, drowsiness, and lethargy have been reported in breastfed infants of mothers taking the herb. Given available evidence, St. John's Wort should be avoided during lactation.

Insulin glargine: insulin does not transfer into breast milk in meaningful amounts, and any that does is degraded in the infant's GI tract before absorption. Continuing Lantus while breastfeeding is generally safe under clinician supervision, with the understanding that breastfeeding itself alters insulin sensitivity and may require dose adjustments.

Contraception requirement:

If you are on Lantus and using combined hormonal contraception, do not add St. John's Wort. If you are already taking St. John's Wort and start Lantus, switch to a non-hormonally interacting contraceptive method (copper IUD, progestin-only pill with backup, or barrier methods) until you have resolved the supplement question with your prescriber.

Who should avoid this combination entirely

Avoid combining St. John's Wort with Lantus if you:

• Have type 1 diabetes (zero endogenous insulin reserve; any blood sugar unpredictability is dangerous)
• Are on a complex regimen that includes a sulfonylurea, meglitinide, or any oral antidiabetic that is a CYP2C9 substrate alongside your basal insulin
• Are trying to conceive, pregnant, or breastfeeding
• Use combined hormonal contraception
• Have a history of severe hypoglycemia or hypoglycemia unawareness
• Are post-menopausal with cardiovascular disease, where hypoglycemic episodes carry elevated cardiac risk

Who might discuss it with a clinician rather than never

A small subset of women might ask whether a low-hyperforin St. John's Wort product could be used with very close monitoring. This conversation is worth having if:

• You have type 2 diabetes with some residual beta-cell function
• You are not on any CYP2C9-substrate co-medications
• You do not use hormonal contraception
• You check your fasting and postprandial glucose at least twice daily
• You have a clinician actively monitoring your HbA1c every three months

Even in this scenario, the evidence base is thin. The Natural Medicines database rates the St. John's Wort and antidiabetic drug combination as a "Moderate" interaction requiring caution, and that rating applies to the class, not specifically to insulin glargine. The honest answer is that no well-powered randomized controlled trial has examined this specific combination in women. That gap means the risk cannot be quantified, only estimated.

What to monitor if your clinician approves continued use

If your clinician reviews your full medication list and decides the combination can be managed, expect to track:

• Fasting blood glucose every morning before your Lantus injection
• Postprandial glucose 2 hours after your largest meal
• Any nocturnal hypoglycemia symptoms (waking with sweating, heart pounding, confusion)
• HbA1c every 3 months rather than every 6
• Mood symptoms, to assess whether St. John's Wort is actually working (most evidence supports benefit over 6-8 weeks; if you are not better by 8 weeks, the risk-benefit equation shifts toward stopping the herb)

Log your glucose readings and bring them to every appointment. Do not adjust your Lantus dose based on glucose readings alone if you are also taking St. John's Wort, because you cannot isolate which variable is driving a change.

Safer alternatives for the reasons women reach for St. John's Wort

If you are using St. John's Wort for depression or perimenopausal mood symptoms while on Lantus, safer options exist:

For mild to moderate depression:

• SSRIs (sertraline, escitalopram) are well-studied in women with diabetes and do not interact with insulin glargine at the pharmacokinetic level. A meta-analysis published in Diabetes Care found that SSRIs modestly improve glycemic control in people with comorbid depression and type 2 diabetes.
• Cognitive behavioral therapy (CBT) has strong evidence for depression and carries no drug interaction risk.

For perimenopausal mood symptoms:

• Low-dose SSRIs or SNRIs (venlafaxine, desvenlafaxine) have evidence for perimenopausal mood and vasomotor symptoms. The Menopause Society supports their use as non-hormonal options.
• The Menopause Society's 2023 position statement confirms that FDA-approved treatments for vasomotor symptoms and mood in menopause include both hormonal and non-hormonal options, none of which carry the interaction profile of St. John's Wort.

For PMDD in reproductive-age women with diabetes:

• Intermittent luteal-phase SSRI dosing has strong evidence and avoids continuous drug exposure.

What to do if you are already taking both

Do not stop either medication abruptly. Stopping Lantus suddenly causes dangerous hyperglycemia. Stopping St. John's Wort suddenly removes the CYP induction, which may cause blood sugar to drop as any co-medications that were being metabolized faster suddenly stay in your system longer.

Contact your prescriber today. Bring your glucose log. Ask specifically: "I am taking St. John's Wort and Lantus together. Can we review my recent glucose readings and decide on a plan to taper the herb safely while monitoring my blood sugar?"

Expect a tapering plan for the St. John's Wort over two to four weeks, with daily glucose monitoring during the taper. Enzyme induction from St. John's Wort resolves in approximately 14 days after the last dose, so your clinician will likely want glucose readings through that window.

If you experience symptoms of hypoglycemia (shakiness, sweating, confusion, heart racing) at any point while tapering, treat with 15 grams of fast-acting carbohydrate and contact your care team. Do not wait until your next scheduled appointment.